Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Not listed Not applicable Interventional

Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

NCT06304207
View directory record Official record
Conditions
Copd, COPD Exacerbation, COPD Bronchitis, Emphysema or COPD, Chronic Lung Disease, Pulmonary Fibrosis, Interstitial Lung Disease, Bronchiectasis, Chronic Asthma, Chronic Asthmatic Bronchitis
Interventions
Onsite Maintenance Exercise Training, Telehealth Maintenance Exercise
Combination Product
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 16, 2026, 8:32 AM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
73
States / cities
Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Not applicable Interventional

Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation

NCT01799330
View directory record Official record
Conditions
COPD
Interventions
Transcutaneous Electrical Muscle Stimulation (TCEMS), Sham TCEMS
Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 2 Interventional

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00098228
View directory record Official record
Conditions
COPD
Interventions
QAB149
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 2 Interventional

Dose Finding Study in COPD

NCT00122434
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 83 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Obstructive Pulmonary Disorder and Acute Exercise

NCT02780219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
stable amino acid infusion, acute exercise with amino acid infusion, 24-hour post exercise amino acid infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431287
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Greer, California • Fort Collins, Colorado • Danbury, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 16, 2026, 8:32 AM EDT
Completed No phase listed Observational

Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00259909
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Infections, Bacterial
Interventions
GSK questionnaire, St. George's Respiratory Questionnaire, Acute Short Form 12 version 2, Global Efficacy questionnaire
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
79
States / cities
Birmingham, Alabama • Hueytown, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT02487498
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anaheim, California • Escondido, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Not applicable Interventional Results available

Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients

NCT03221387
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Hypercapnia, Hypoxia
Interventions
Humidified nasal high flow with oxygen
Device
Lead sponsor
Temple University
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 16, 2026, 8:32 AM EDT
Terminated Phase 3 Interventional Results available

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

NCT02722304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions
ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 16, 2026, 8:32 AM EDT
Terminated Not applicable Interventional

Promoting Activity After COPD Exacerbations, Aim 2

NCT03793192
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PACE2 Intervention
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers

NCT00565214
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Group 1, Group 2
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 16, 2026, 8:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

NCT01793649
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
Interventions
GS-5737
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Not applicable Interventional Results available

Outlook Quality of Life Intervention

NCT00784095
View directory record Official record
Conditions
Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Life completion and preparation, Attention Control
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 16, 2026, 8:32 AM EDT
Active, not recruiting Not applicable Interventional

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166
View directory record Official record
Conditions
COPD, Smoking, Tobacco Use
Interventions
Cigarette, THS
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
40 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Clearwater, Florida • Coral Gables, Florida • Davie, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Levalbuterol HCl, Albuterol Sulfate, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
20
States / cities
Carmichael, California • Spring Valley, California • Wheat Ridge, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT03256695
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol sulfate (ABS)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Andalusia, Alabama • Anniston, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

NCT02238483
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
AZD7624 1.0 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 16, 2026, 8:32 AM EDT
Recruiting No phase listed Observational

Lung Microbiome and Inflammation in Early COPD

NCT02777879
View directory record Official record
Conditions
Chronic Obstuctive Pulmonary Disease
Interventions
Bronchoscopy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease

NCT01372462
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NIOV - Room Air, NIOV - Oxygen, Nasal Cannula Oxygen
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

NCT00363805
View directory record Official record
Conditions
Lung Cancer Prevention
Interventions
green tea, Polyphenon E, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Sherry Chow
Other
Eligibility
40 Years to 80 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Not applicable Interventional Results available

Advance Care Planning in the Emergency Department

NCT05209880
View directory record Official record
Conditions
Congestive Heart Failure, Metastatic Cancer, Chronic Kidney Disease Requiring Chronic Dialysis, Chronic Obstructive Pulmonary Disease
Interventions
ED GOAL
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 16, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

NCT03937479
View directory record Official record
Conditions
COPD
Interventions
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
50
States / cities
Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 16, 2026, 8:32 AM EDT